医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Byte Plans to Donate 25,000 Oral Health Care Kits to Afghan Refugees

2021年08月30日 PM09:00
このエントリーをはてなブックマークに追加


 

LOS ANGELES

Byte, a rapidly growing clear aligner company, announced today they will donate at least 25,000 oral health kits to Afghan refugees who are being resettled in the United States.

“Our company was distraught by the humanitarian crisis that has unfolded,” said Byte CEO Neeraj Gunsagar. “Families who, for decades, fought for freedom are being forced to leave their homes and lives behind. None of us can imagine what they are going through right now. The least Byte can do is ensure the refugees have some oral health essentials in this period of upheaval. We encourage companies that are in the position to help to join us in doing so. Helping the Afghan refugees is our moral responsibility.”

Byte will donate the oral health kits through its philanthropic arm, ByteCares. The oral health kits consist of a toothbrush, toothbrush cover, toothpaste, floss, a timer, and a travel pouch.

In early 2020, ByteCares responded to the personal protective equipment shortage by quickly diverting its manufacturing resources to make reusable face shields and ventilator parts and donating face masks that were shipped to first responders and medical facilities across the country.

About Byte

Byte is a leader in the at-home clear aligner market. Byte was acquired in January 2021 by Dentsply Sirona Inc. (XRAY). With a growing team of over 500 employees globally and headquartered in Los Angeles, Byte’s nationwide network of licensed dentists and orthodontists oversees every customer’s treatment plan, delivering a highly-rated consumer experience and results at a fraction of the cost of traditional methods. At under $85 per month, Byte has found a way to make the inaccessible, accessible — providing an easy, convenient and affordable way to upgrade your smile. For more information on Byte, visit: www.byteme.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005192/en/

CONTACT

Byte Press Office

pr@byteme.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™